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A-kinase anchoring proteins (AKAPs) tether protein kinase
A (PKA) and other signaling proteins to defined intracellular
sites, thereby establishing compartmentalized cAMP signaling.
AKAP-PKA interactions play key roles in various cellular pro-
cesses, including the regulation of cardiac myocyte contractil-
ity. We discovered small molecules, 3,3-diamino-4,4-dihy-
droxydiphenylmethane (FMP-API-1) and its derivatives, which
inhibit AKAP-PKA interactions in vitro and in cultured car-
diac myocytes. The molecules bind to an allosteric site of regu-
latory subunits of PKA identifying a hitherto unrecognized
region that controls AKAP-PKA interactions. FMP-API-1 also
activates PKA. The net effect of FMP-API-1 is a selective inter-
ference with compartmentalized cAMP signaling. In cardiac
myocytes, FMP-API-1 reveals a novel mechanism involved in
terminating -adrenoreceptor-induced cAMP synthesis. In
addition, FMP-API-1 leads to an increase in contractility of
cultured rat cardiac myocytes and intact hearts. Thus, FMP-
API-1 represents not only a novel means to study compart-
mentalized cAMP/PKA signaling but, due to its effects on car-
diac myocytes and intact hearts, provides the basis for a new
concept in the treatment of chronic heart failure.
Cyclic AMP (cAMP)-dependent protein kinase (protein
kinase A; PKA)3 is a ubiquitous serine/threonine kinase con-
trolling a variety of cellular functions. PKA holoenzyme con-
sists of a dimer of regulatory subunits (RI, RI, RII, or
RII) and two catalytic subunits (C, C, or C), each bound
to an R subunit. RI-containing holoenzyme is termed PKA
type I, whereas RII-containing PKA is termed PKA type II.
Binding of cAMP to the R subunits induces a conformational
change, causing the release and thus activation of the catalytic
subunits, which then phosphorylate various substrates (1).
Specificity of PKA action is achieved by controlling its cellular
localization through a family of A-kinase anchoring proteins
(AKAPs).
AKAPs bind PKA through an amphipathic -helical struc-
ture consisting of 14–18 amino acids (RII-binding domain),
which interacts with the hydrophobic groove formed by the
N-terminal dimerization and docking (D/D) domain of regu-
latory subunit dimers (2–5). Besides PKA, AKAPs can directly
bind various signaling proteins, such as other protein kinases,
protein phosphatases, cAMP phosphodiesterases (PDEs),
GTP-binding proteins, adaptor proteins, and substrate pro-
teins of PKA. Thus, AKAPs coordinate multiprotein signaling
complexes, thereby establishing compartmentalized signaling
(6–9).
The functional roles of AKAP-PKA interactions have often
been uncovered in in vitro and in cell-based studies by disrup-
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tion of the interactions using peptides derived from the RII-
binding domains of AKAPs. Several such peptides have been
developed (6). For example, peptide Ht31 was derived from
the RII-binding domain of AKAP-Lbc (10), AKAP in silico
(AKAPIS) was derived from a bioinformatics approach (11),
superAKAPIS was derived from AKAPIS (4), and others were
derived from the RII-binding domain of AKAP18 (12). Pep-
tides like these have, for instance, been used to uncouple PKA
from AKAPs in cardiac myocytes and thereby to demonstrate
that AKAP-PKA interactions facilitate -adrenoreceptor-
induced increases in cardiac myocyte contractility (13).
Although peptides have proven invaluable for such pur-
poses, their restricted membrane permeability and poor oral
availability limit their use for therapeutic purposes and in ani-
mal studies. These drawbacks may be overcome with small
molecules. Various examples show that disruption of protein-
protein interactions with small molecules is feasible. Both
small molecules interfering with interactions by association
with the interacting surfaces or by allosteric binding have
been identified (14–16). The specificity and diversity of pro-
tein-protein interactions permits highly selective pharmaco-
logical interference. Thus, targeting protein-protein interac-
tions with small molecules opens new avenues for the study of
molecular mechanisms. In addition, the development of small
molecules targeting disease-relevant protein-protein interac-
tions may lead to novel therapeutic strategies, which, poten-
tially, result in higher specificity and fewer side effects.
Here we report the discovery of small molecules that have a
dual effect. FMP-API-1 and its derivatives inhibit AKAP-PKA
associations and also activate PKA. Using cardiac myocytes,
we show that these molecules provide a new means to analyze
functions of compartmentalized cAMP/PKA signaling. More-
over, we show that the approach of targeting scaffolding pro-
teins with small molecules may pave the way to a novel con-
cept for the treatment of chronic heart failure.
EXPERIMENTAL PROCEDURES
Generation of Recombinant RII Subunits and AKAP18—
Recombinant AKAP18 was generated as a fusion with glu-
thatione S-transferase (GST) as described (17). Full-length
PKA RII (17) was subcloned from pGEX-4T-3 into the
Profinity eXact pPAL7 vector, creating a Profinity exact fu-
sion tag N-terminal to the recombinant protein (Bio-Rad).
Deletion mutants were amplified by PCR from the RII full-
length template and cloned into pPAL7 via BamHI and NotI
restriction sites. RII variants were expressed in Escherichia
coli (strain Rosetta DE3). Tag-free RII proteins were affinity-
purified as recommended by the supplier of the Profinity ex-
act fusion tag system (Bio-Rad). The final polishing step was a
gel filtration with Superdex 75 (GE Healthcare) in 20 mM
HEPES, 300 mM NaCl, pH 7.
ELISA-based Screening of a Small Molecule Library—An
ELISA-based assay, established for the detection of the
AKAP18-RII interaction (12), was used for screening a
small molecule library (FMP_20.000) with 20,064 compounds
in 384-well plates.
Synthesis of FMP-API-1 Analogues—Syntheses of FMP-
API-1 and derivatives (Table 1) followed published proce-
dures from commercially available precursors in one or two
steps. Purity of all compounds was monitored by reversed-
phase HPLC applying a gradient from water to 100% acetoni-
trile within 60 min at a flow rate of 1 ml/min. Exemplary pro-
cedures are briefly described below.
Synthesis of FMP-API-1—Bis-(4-hydroxyphenylmethane)
was nitrated by diluted nitric acid to yield 3,3-dinitro-4,4-
dihydroxydiphenylmethane, which was subsequently reduced
with palladium/charcoal (10%) in a hydrogen atmosphere.
Flash chromatography on silica with dichloromethane/metha-
nol (15:1) gave pure 3,3-diamino-4,4-dihydroxydiphenyl-
methane as a gray solid. C13H14N2O2; MW 230,3; CAS
[16523-28-7]; purity 99.4%; yield 70%; UV: max 293 nm.
Synthesis of 4-Benzyl-pyrocatechol (Compound
FMP-API-1/27)—Compound FMP-API-1/27 was synthesized
by catalytic reduction of 3,4-dihydroxybenzophenone in
methanol for 6 h at ambient temperature, applying a hydro-
gen atmosphere and palladium/charcoal (10%). Purification
was achieved by flash chromatography on silica with petrol
ether/ethyl acetate (4:1) to yield a gray solid. C13H12O2; MW
200,08; CAS [7005-43-8]; purity 97.5%; yield 90%; UV: max
285 nm.
Surface Plasmon Resonance Measurements—Solution com-
petition assays based on surface plasmon resonance (SPR)
were performed using streptavidin-coated sensor chips (GE
Healthcare) to capture the N-terminally biotinylated peptide
AKAP18-L314E, derived from the RII-binding domain of
AKAP18 (12). Binding of human PKA regulatory subunit
RII or RII to the AKAP18-L314E peptide surface and inhi-
bition of RII binding by tested compounds were analyzed us-
ing a Biacore 3000 instrument (GE Healthcare) as described
(17–19). Regulatory RI subunits were captured on 8-AHA-
cAMP surfaces, and association of an AKAP149 fragment
(amino acids 285–387) encompassing its RI/RII-binding do-
main was investigated as described (19). Where indicated,
RI, RI, RII, and RII were bound to 8-AHA-cAMP-cou-
pled sensor chips as described (19). For direct binding studies,
a Biacore S51 instrument (GE Healthcare) was used to moni-
tor compound binding to immobilized RII. In brief, S CM-5
chips were used to immobilize 10000 RU of RII (20 g/ml in
10 mM acetate pH 4.5) via standard amine coupling as recom-
mended by the manufacturer. Interaction studies were per-
formed in running buffer (25 mM Tris, pH 7.4, 150 mM NaCl,
50 M EDTA, 5% DMSO, and 0.005% surfactant P20) at 25 °C.
Nonspecific binding was subtracted using an N-hydroxysuc-
cinimide (NHS)/ethyl-N-(3-diethylaminopropyl)carbodiimide
(EDC) activated/deactivated blank surface, and a DMSO cali-
bration procedure was performed to subtract artifacts caused
by the solvent. FMP-API-1, FMP-API-1/27, Ht31, and combi-
nations thereof were injected for 60 s at a flow rate of 30 l/
min, and the dissociation phase was monitored for 180 s. The
surface was regenerated by a 30 s injection of 10 mM glycine,
pH 9.5.
Nuclear Magnetic Resonance Measurements—All experi-
ments were performed on a Bruker DRX600 spectrometer
equipped with a z axis gradient 5-mm TXI Cryoprobe at 300
K. NMR samples of unlabeled RII (14 M), GST-AKAP18,
and ovalbumin (19 M each) were prepared in 20 mM phos-
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phate buffer (pH 7.4), and 1 mM FMP-API-1 in DMSO-d6 was
added to each. The final protein samples contained 2%
DMSO-d6. Saturation transfer difference (STD) NMR experi-
ments were recorded with the carrier frequency set at 0.68
ppm for on-resonance irradiation and about 330 ppm for off-
resonance irradiation. A train of 50 Gaussian-shaped pulses at
40 ms was applied, each separated by a 1-ms delay, for a total
duration of 2.05 s, to achieve selective protein saturation. Ac-
quisition of spectra was done with 32 scans and a relaxation
delay of 1.3 s. A T1 spin-lock pulse of 40 ms was used to sup-
press the background protein signals. The STD spectrum was
obtained from the internal subtraction of the on-resonance
from the off-resonance data by phase cycling (20).
Preparation of Rat Neonatal and Adult CardiacMyocytes—
Neonatal cardiac myocytes were obtained fromWistar Kyoto
(WKY) rats (1–2 days old). Primary cultures of adult cardiac
myocytes from male WKY rats aged 3 months were per-
formed as described previously (21).
Immunoprecipitation, cAMP-agarose Pull-down and RII
Overlay Assays, Preparation of Cell Lysates, and Western
Blotting—The experiments were carried out as described pre-
viously by us (17, 18, 22–24). AKAP150, phospho-phospho-
lamban (both from Upstate), cardiac troponin I (c-TnI), c-TnI
phosphorylated at Ser23/24, PKA substrates phosphorylated by
PKA at the consensus site RRX(S/T) (all from Cell Signaling
Technology, Boston, MA), Yotiao (Novus Biologicals Inc.,
Littleton, CO), calsequestrin (GeneTex, San Antonio, TX),
catalytic C, RII, and RII subunits of PKA (BD Biosci-
ences), and AKAP18 (17) were detected by Western blot
with specific primary and peroxidase-conjugated secondary
antibodies. Immunoprecipitations of RII subunits and
AKAP150 were carried out with the antibodies listed above.
Signals were visualized using Lumi-Light Western blotting
substrate solution and the Lumi Imager F1 (Roche Applied
Science) (17). AKAPs were detected by RII overlay with 32P-
labeled recombinant RII subunits (17).
Cyclic AMP and Adenylyl Cyclase Assay—Radioimmunoas-
says were carried out to determine cAMP levels in rat neona-
tal cardiac myocytes as described (24). Cyclic AMP accumula-
tions in uterine tissue samples were detected in the presence
of the nonspecific phosphodiesterase inhibitor 3-isobutyl-1-
methylxanthine by a competitive cAMP enzyme immunoas-
say kit. Adenylyl cyclase activity was assayed in HEK293 cells
transiently expressing cyclic nucleotide-gated channels
(CNGC) as cellular cAMP biosensors to measure changes in
subplasmalemmal cAMP as described (25).
Kinase Activity Assays—The non-radioactive PepTag PKA
assay (Promega, Madison, WI) was used to measure PKA ac-
tivity from cell lysates and immunoprecipitates and to mea-
sure activity of recombinant catalytic subunits. The PepTag
PKA assay is based on the phosphorylation of the fluorescent
PKA substrate peptide, Leu-Arg-Arg-Ala-Ser-Leu-Gly
(Kemptide) (PepTag A1 peptide), which, upon phosphoryla-
tion by PKA, acquires a negative charge and can be separated
from the non-phosphorylated peptide by agarose gel
electrophoresis.
To measure PKA activity in cell lysates, rat neonatal cardiac
myocytes were plated onto 6-well tissue culture plates at a
density of 2 106 cells/well. Myocytes were serum-starved
overnight prior to the experiments, which were carried out 2
days after seeding. Small molecules, FMP-API-1 or FMP-API-
1/27, were added to the medium as indicated in the figure
legends. Cells were incubated for 30 min. Medium was re-
moved, and cells were homogenized in 100 l/well lysis buffer
(10 mM K2HPO4, 150 mM NaCl, 5 mM EDTA, 5 mM EGTA,
1% Triton X-100, 0.25% deoxycholate, 1 mM benzamidine, 0.5
mM phenylmethanesulfonyl fluoride, 3.2 g/ml trypsin inhibi-
tor I-S, 1.4 g/ml aprotinin). The lysates were cleared by cen-
trifugation (12,000 g, 4 °C, 10 min). The supernatants were
assayed for PKA activity in the absence of added cAMP. Pep-
Tag A1 peptide (0.056 g/l) was incubated with 15 l of the
supernatant in PepTag PKA reaction buffer (final volume 25
l) at 30 °C for 10 min. The reaction was stopped by boiling
the samples for 10 min. Phosphorylated and non-phosphory-
lated PepTag A1 peptides were separated by 0.8% agarose gel
electrophoresis. Fluorescence was recorded with the Lumi
Imager F1 (Roche Applied Science), and bands were analyzed
by densitometry.
To measure PKA activity in AKAP150-immunoprecipi-
tates, AKAP150 was immunoprecipitated as described (17).
Protein A-Sepharose beads were resuspended in 100 l of
lysis buffer, and 14.3-l bead suspensions were incubated
with PepTag A1 peptide (0.056 g/l), and 5 l of PKA acti-
vator solution (cAMP) in PepTag PKA reaction buffer (final
volume 25 l) at 30 °C for 10 min. The assay was continued as
described above.
To measure the activity of PKA catalytic subunits in vitro, 5
l of recombinant catalytic subunits (0.0167 mg/ml) were
incubated with PepTag A1 peptide (0.056 g/l) in PepTag
PKA reaction buffer (final volume 25 l) at 30 °C for 10 min
with or without 0.013 mg/ml recombinant RII subunits or
0.04 M cAMP or FMP-API-1 as indicated in the figure leg-
ends. The assay was continued as described above.
The effect of FMP-API-1 (100 M) on ErbB1, MEK1, ERK1
and -2, ROCK1 and -2, PKC, CaMKII, and GSK3 activi-
ties was assayed using Invitrogen’s SelectScreen commercial
profiling service.
Phosphatase and PDE4 Activity Assays—Calcineurin was
assayed using the Calcineurin Cellular Assay Kit Plus from
Biomol GmbH (Hamburg, Germany) according to the manu-
facturer’s instructions. For analysis of neonatal rat cardiac
myocyte cell lysates, cells were seeded in 6-well plates (2
106 cells/well), cultured for 24 h, and treated with DMSO (1%)
or FMP-API-1 (in the indicated concentrations, 30 min). Af-
ter washing three times with TBS, cells were detached from
the wells with a cell scraper and suspended in ice-cold lysis
buffer (270 l). Samples were centrifuged (10 min,
22,000  g, 4 °C), and activities of Ca2-independent phos-
phatases and calcineurin were assessed. To measure the
specific influence of FMP-API-1 on calcineurin, the recom-
binant enzyme included in the kit was diluted 1:6.25 in ly-
sis buffer, and FMP-API-1 was added. PDE4 activities were
measured using 20 g of protein, in 25 l of cell lysates
prepared from neonatal cardiac myocytes as described (24).
Electrophysiology—Whole-cell L-type ICa (Ca2 current)
was recorded from rat neonatal cardiac myocytes (see
Small Molecule Inhibitors of AKAP-PKA Interactions
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above) as described previously (16). For measurements of
IKs channel currents, COSM7 cells were utilized as de-
scribed (26, 27).
Contractility of Isolated Perfused Heart Preparations—Hearts
were obtained fromWKY rats (12-week-old males) and sub-
jected to Langendorff heart experiments as described (28).
In Vitro Uterus Contractility Studies—All experiments in-
volving animal subjects were carried out with the approval of
the Hungarian Ethical Committee for Animal Research (regis-
tration number IV/01758-2/2008) and under the control of
the ISO-9001:2008 Quality Management System. Sexually
mature female Sprague-Dawley rats (body mass 140–160 g,
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50–60 days old) were mated in the early morning hours. Cop-
ulation was confirmed by the presence of a copulation plug or
spermatozoa in the vagina. The day of copulation was consid-
ered to be the first day of pregnancy.
On day 22 of pregnancy, the rats were sacrificed (CO2 inha-
lation), and the uteri were removed and prepared for the in
vitro contractility assay. The isolated uterine horns were im-
mediately placed in an organ bath (de Jongh solution; con-
taining 137 mM NaCl, 3 mM KCl, 1 mM CaCl2, 1 mM MgCl2,
12 mM NaHCO3, 4 mM Na2HPO4, 6 mM glucose, pH 7.4) per-
fused with 95% oxygen and 5% carbon dioxide. They were
trimmed of fat, and the feto-placental units were removed.
Temperature was maintained at 37 °C. Four rings 1 cm long
were sliced from the middle part of each horn, including im-
plantation sites, and tested in parallel. They were mounted
vertically between two platinum electrodes in the above-men-
tioned organ bath under the same conditions. After mount-
ing, the initial tension was set at 1.5 g, and the rings were
equilibrated for 60 min. Then rhythmic contractions were
elicited by 25 mM KCl. The tension of the myometrial rings
was measured with a strain gauge transducer (SG-02, Expe-
rimetria Ltd., Budapest, Hungary), recorded, and analyzed by
the SPEL advanced ISOSYS data acquisition system (Expe-
rimetria Ltd.). Areas under the curves of 4-min periods of
each concentration were evaluated. The maximal contraction-
inhibiting values were calculated with the Prism 4.0 computer
program (GraphPad Inc., San Diego, CA).
Statistics—One-way analysis of variance, Dunnett’s multi-
ple comparison test, and single- and double-tailed Student’s t
test were carried out for statistical analyses as indicated.
RESULTS
FMP-API-1 Inhibits AKAP-PKA Interactions by Allosteric
Non-covalent Binding to Regulatory Subunits of PKA—In or-
der to identify small molecules disrupting AKAP-PKA inter-
actions, we developed an ELISA-based screening assay, where
full-length AKAP18 was added to RII subunits of PKA
bound to 384-well microtiter plates. Interaction was detected
using primary antibodies specific for AKAP18, secondary
peroxidase-conjugated antibodies, and a chemiluminescent
peroxidase substrate (Fig. 1A) (12). The assay was validated
using the PKA anchoring disruptor peptide, AKAP18-L314E,
derived from the RII-binding domain of AKAP18 (12). This
peptide inhibited the AKAP18-RII subunit interaction with
an IC50 value of 10 nM, whereas the inactive control peptide
AKAP18-PP did not affect the interaction in concentrations
of up to 1 mM (Fig. 1A). Using this assay system, 20,000 small
molecules were screened (FMP small molecule library
FMP_20,000). The molecules possess an average molecular
mass of 250 Da and were selected on the basis of a large
chemical diversity. They have druglike properties in that they
fulfill the Lipinski rules to increase bioavailability (29). Nine
compounds were identified as potential disruptors of the
AKAP18-RII subunit interaction.
The most promising candidate, compound FMP-API-1
(IC50 23.3 M; Fig. 1A), was selected for validation in a sec-
ondary assay, SPR measurements. In the SPR measurements,
the peptide AKAP18-L314E was immobilized on the chip
surface, and recombinant RII subunits preincubated with
FMP-API-1 (50 M) were added. FMP-API-1 inhibited the
interaction by40% (Fig. 1B).
For initial structure-activity relationship investigations, a
focused library of 26 derivatives of FMP-API-1 was synthe-
sized (Table 1). SPR measurements revealed that only deriva-
tives FMP-API-1/27 and FMP-API-1/28 disrupted the inter-
action of the peptide AKAP18-L314E with RII subunits
effectively. At a concentration of 50 M, FMP-API-1/27 and
FMP-API-1/28 inhibited the interaction of RII subunits with
the peptide by 75 and 70%, respectively (Fig. 1B). Titrations
revealed that FMP-API-1/27 inhibited the interaction of RII
subunits with the peptide AKAP-18-L314E with IC50
4.0 0.1 M (Fig. 1C). In contrast to FMP-API-1, neither
FMP-API-1/27 nor FMP-API-1/28 contains any amino
groups, suggesting that these groups are not involved in the
interaction with the target protein, leading to inhibition of the
interaction. In addition, the structure of FMP-API-1/28 sug-
gests that the addition of a keto function to the central meth-
ylene group connecting the two aromatic systems does not
impair the activity. Thus, possible steric hindrance caused by
the keto function or the decreased flexibility in the center
of the active pharmacophore apparently did not interfere with
FIGURE 1. FMP-API-1 inhibits the interaction between AKAP18 and RII by allosteric binding to the RII subunits. A, microtiter plates were coated
with RII (15 ng/well) and incubated with AKAP18 (15 ng/well) in the presence of the PKA anchoring disruptor peptide AKAP18-L314E, the inactive con-
trol peptide AKAP18-PP, or FMP-API-1 in the indicated concentrations (12). Binding of AKAP18 to RIIwas detected by incubation with primary anti-
AKAP18 (A184 antibody (17)) and secondary peroxidase-coupled antibodies and subsequently with a chemiluminescence peroxidase substrate solution.
Signals were recorded in a luminescence intensity reader (n 5; shown are means S.E. (error bars)). AKAP18-L314E and AKAP18-PP curves are signifi-
cantly different (p 0.01), and the FMP-API-1 inhibition curve is significantly different from the control (DMSO) (p 0.05). The structure shows FMP-API-1.
B, SPR measurements confirming the inhibitory effect of FMP-API-1 and its derivatives FMP-API-1/26, -27, and -28. The peptide AKAP18-L314E was coupled
to sensor chip surfaces, and RII (500 nM), preincubated with the small molecules (50 M), was added. As a control, the small molecules were omitted.
Shown are means from two independent experiments. C, FMP-API-1 inhibits the interactions between regulatory RII and RII subunits of PKA with the
peptide AKAP18-L314E. The peptide was coupled to SPR sensor chips, and RII and RII, preincubated with FMP-API-1/27 (391 nM to 200 M), were added
to determine the IC50 values for the inhibitory effect of the molecule. Shown are means from two independent experiments. D, 8-AHA-cAMP was coupled
to SPR sensor chips, and RI subunits were captured on the surface. AKAP149 was added in the absence or presence of FMP-API-1/27. Shown is the result of
one of two independent experiments. E, the peptide Ht31 and the small molecules FMP-API-1 and FMP-API-1/27 bind additively to RII. Association and
dissociation of the small molecules (100 M) and Ht31 (50 nM), either alone or in the indicated combination, were measured by SPR using a sensor chip
coated with full-length RII. Shown are means from two independent experiments. F, FMP-API-1 binds to full-length PKA RII. Top, reference NMR spectrum
of FMP-API-1 (1 mM) in the presence of RII (14 M). Asterisks indicate the proton signals of the compound. Bottom, STD NMR spectrum of FMP-API-1 (1 mM)
in the presence of RII (14 M). Shown are representative spectra from three independent experiments. G, the indicated versions of RIIwere generated
and preincubated with the FMP-API-1 derivative FMP-API-1/27 (50 M), and binding to the peptide AKAP18-L314E was assessed by SPR measurements as
described in B and C. Shown are means from two independent experiments. H, 8-AHA-cAMP was coupled to SPR sensor chips, and regulatory subunits of
PKA (RI, RI, RII, and RII), preincubated with FMP-API-1/27 (50 M), were added. Shown are means from two independent experiments.
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TABLE 1
Focused library of FMP-API-1 derivatives
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the interaction. Removal of the two hydroxyl groups in the 3-
and 4-positions from one of the aromatic systems of FMP-
API-1/28, yielding FMP-API-1/26, abolished the inhibitory
action of FMP-API-1/28. The structure of the inactive com-
pound FMP-API-1/30, possessing methoxy (-OCH3) and
amino (-NH2) groups instead of hydroxyl (-OH) groups, con-
firms that the hydroxyl groups are relevant for the inhibitory
effect of the molecules. It is possible that the hydroxyl groups
serve as hydrogen bond donors, facilitating the interaction of
the compound with hydrogen bond acceptors in the target
protein.
Due to the similarity between RII and RII subunits, the
interactions between both subunits and AKAPs may be inhib-
ited by the small molecules. Therefore, SPR experiments, set
up as described above, were also used to quantitatively deter-
mine the inhibitory effects of FMP-API-1/27 on the interac-
tion of RII subunits with the AKAP18-derived peptides.
Fig. 1C shows that FMP-API-1/27 inhibits the interactions
with IC50 10.7 1.8 M, suggesting that the molecule has
similar effects on RII- and RII-AKAP interactions. A differ-
ent SPR experiment was established for investigating the ef-
fect of FMP-API-1/27 on regulatory RI subunit interactions
with AKAPs. RI subunits were captured on 8-AHA-cAMP
sensor chip surfaces, and a fragment of the dual specificity
AKAP, D-AKAP1 (AKAP149) encompassing the RI/RII inter-
acting domain (amino acids 285–387) (30) was allowed to
bind to the RI subunits in the absence or presence of FMP-
API-1/27. The small molecule inhibits the interaction by
around 75% (Fig. 1D). RI cannot be tested in this setup be-
cause it does not bind to D-AKAP1 (19). Thus, the small mol-
ecules inhibit both RI and RII interactions with AKAPs. The
following exemplary experiments were carried out with RII
subunits.
With the AKAP18-derived peptides coupled to the Bia-
core sensor chips, the SPR experiments (Fig. 1, B and D) were
designed in such a way that the small molecules require either
interference with the interacting surfaces or allosteric binding
to RII subunits to inhibit the interaction. In order to investi-
gate whether the small molecules act through interference
with the interacting domains, SPR sensor chips were coated
with full-length RII, and the association and dissociation of
FMP-API-1, FMP-API-1/27, and Ht31 or each small molecule
combined with the peptide was measured (Fig. 1E). The addi-
tive association curve resulting from the combination of small
molecule and peptide suggests binding of the small molecules
to an allosteric site on RII rather than to the D/D domain. In
addition, the additive binding of the PKA disruptor peptide
Ht31 along with FMP-API-1 would not be observed if the
small molecule interfered with R subunit dimerization be-
cause this is required for AKAP binding. In line with these
observations, the D/D domain coupled to an SPR sensor chip
did not bind the small molecules (data not shown), and
1H,15N HSQC NMR experiments with 15N-labeled RII D/D
domain (residues 1–44) showed no binding of FMP-API-1
(0.1–2 mM; supplemental Fig. 1).
To confirm that the inhibitory effect is mediated by binding
of the molecules to the R subunits, NMR STD experiments
(20) were performed with FMP-API-1 and full-length RII sub-
units (Fig. 1F). A reference proton spectrum of FMP-API-1
and a STD spectrum of the full-length PKA RII-FMP-API-1
TABLE 1—continued
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sample were recorded (Fig. 1F). The resonance signals of
FMP-API-1 in the STD spectrum indicated binding of the
compound to the full-length RII subunit. Binding of FMP-
API-1 to an unrelated protein, ovalbumin, was not observed
(data not shown). Binding of FMP-API-1 to the full-length
RII subunit is noncovalent and reversible (Fig. 1F). This can
be concluded from the STD NMR experiments, which gener-
ally detect reversible interactions (20). If the binding were
covalent, the line width of the small molecule signals would
change drastically. Additional support for non-covalent bind-
ing of FMP-API-1 to RII subunits stems from mass spectro-
metric analyses of recombinant RII subunits after incubation
with the compound (2 h, room temperature). In these experi-
ments, FMP-API-1-modified amino acids within RII sub-
units were not detected (data not shown).
Further confirmation that the binding site of FMP-API-
1/27 in RII subunits is located C-terminal to the D/D do-
main stems from SPR experiments using the truncations of
RII indicated in Fig. 1G. In these experiments, FMP-API-
1/27 (50 M) was preincubated with the full-length RII or
the truncations. The molecule reduced the binding of full-
length RII subunits (amino acids 1–404) to the AKAP18-
derived peptides coupled to the sensor chips to15–20%.
Consistent with the data illustrated in Fig. 1E and supplemen-
tal Fig. 1, it did not affect the interaction of the peptide with
the D/D domain (RII 1–44) or extended versions thereof
(RII 1–44, 1–72, and 1–87). Further elongation to amino
acid 366 (constructs RII 1–259 and RII 1–366) impaired
the inhibitory effect of the compound to the peptides on the
sensor chips (reduction in binding to 60–70%). STD NMR
experiments showed that the observed inhibition was due to
direct binding of FMP-API-1 to the relevant RII truncates
because binding was detected for RII 1–259 and RII 1–366,
but not for RII 1–44, RII 1–72, and RII 1–87 (data not
shown). A shorter construct (RII 1–156) proved to be un-
folded in STD NMR experiments. Its interaction with the
small molecules could therefore not be evaluated in SPR (Fig.
1G) or STD NMR experiments.
Next, we investigated whether the interaction of FMP-
API-1 with a region C-terminal of the D/D domain interferes
with the interaction of the regulatory subunits with cAMP
(Fig. 1H). Regulatory subunits were preincubated with FMP-
API-1/27 and captured on 8-AHA-cAMP sensor chips. This
experiment revealed that FMP-API-1/27 hardly affected bind-
ing of the RI and - subunits to cAMP. In contrast, binding
of RII to cAMP was reduced by 50%, and that of RII sub-
units was reduced by90%. The inhibitory effect of the mole-
cules on the interaction of RII subunits with cAMP was con-
firmed in cAMP-agarose precipitation experiments (Fig. 2B).
However, this revealed that in cells, this effect was far less
pronounced because around 75% of RII could be precipi-
tated in the presence of FMP-API-1 compared with control.
Collectively, the data indicate that FMP-API-1/27 binds
C-terminally from the D/D domain. This region of regulatory
subunits is apparently also crucial for the binding of AKAPs.
The region between amino acids 88 and 156 encompasses the
autoinhibitory domain of PKA that is involved in the inhibi-
tion of catalytic subunits in the holoenzyme. Targeting a re-
gion involving the autoinhibitory domain with small mole-
cules may not only displace RII subunits from AKAPs but
may also modulate the activity of PKA. Indeed, as we show
below, both FMP-API-1 and FMP-API-1/27 activate the ki-
nase (Fig. 3 and supplemental Fig. 2A).
FMP-API-1 and FMP-API-1/27 Disrupt AKAP-PKA Inter-
actions in Cardiac Myocytes—The effect of FMP-API-1 on
AKAP-PKA interactions in a cellular environment was inves-
tigated in rat neonatal cardiac myocytes. Initially, immuno-
precipitation experiments were performed (Fig. 2A).
AKAP150 was immunoprecipitated from cells left untreated
or treated with FMP-API-1 (300 M), isoproterenol (ISO; 100
nM), or a combination of the two. Immunoprecipitation of
AKAP150 was confirmed by Western blotting (Fig. 2A, top).
Compared with the precipitates obtained with preimmune
serum, AKAP150 was strongly enriched in precipitates ob-
tained with specific anti-AKAP150 antibodies. If FMP-API-1
displaced PKA from AKAPs, immunoprecipitates from FMP-
API-1-treated cells are expected to contain less PKA activity
than precipitates from untreated cells. Indeed, immunopre-
cipitates from cells treated with FMP-API-1 contained signifi-
cantly less PKA activity than those from untreated cells (Fig.
2A). Isoproterenol induces PKA activation (i.e. release of cata-
lytic subunits from R subunits). Fig. 2A shows that ISO con-
sistently caused a weak decrease in PKA activity in the precip-
itates. FMP-API-1 decreased the AKAP150-associated PKA
activity to a significantly larger degree. This effect was not
further enhanced if FMP-API-1 was combined with
isoproterenol.
Additionally, the effect of FMP-API-1 on AKAP-PKA inter-
actions in neonatal cardiac myocytes was investigated in
cAMP-agarose precipitation experiments. The cells were
treated with FMP-API-1 (100 M) and lysed, and a cAMP-
agarose precipitation assay was performed. Cyclic AMP-aga-
rose retains regulatory subunits of PKA, including associated
binding proteins, such as AKAPs. Western blot analysis of
cAMP-agarose eluates revealed that consistently fewer RII
subunits were recovered in the presence of FMP-API-1 (Fig.
2B). However, the difference between the amount of RII pre-
cipitates and the amount of RII precipitates obtained from
untreated controls was not significant. The less pronounced
inhibitory effect of FMP-API-1/27 on the interaction of RII
subunits with the cAMP on the agarose compared with the
interaction with cAMP on SPR sensor chips (Fig. 1H) may be
explained by differences in the experimental setups. In the
SPR experiments, the interaction of RII subunits with cAMP
occurs under flow, which may impair a transient interaction
of RII with cAMP and lead to a significant decrease in RII
binding to cAMP. In the cAMP-agarose experiment, the cells
are incubated with the compound for 30 min. The cells are
lysed, and the lysates are incubated with cAMP-agarose over-
night in the presence of FMP-API-1. Compared with the SPR
setup, we deem the results from the cAMP-agarose precipita-
tions to be physiologically more similar to the cellular systems
used to characterize FMP-API-1 (see below). The amounts of
several AKAPs precipitated with the cAMP-agarose were sig-
nificantly reduced, whereby the amounts of AKAP18,
AKAP150, and AKAP Yotiao were reduced to a lower degree
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than explained by the lower amount of RII subunits precipi-
tated in the presence of the small molecule. The data indicate
that FMP-API-1 inhibits AKAP-PKA interactions in cells (Fig.
2B). For the simultaneous detection of all AKAPs in the
cAMP-agarose precipitates, an RII overlay assay was applied.
This assay detected various RII-binding proteins in cAMP-
agarose precipitates obtained from untreated cells. Consistent
with the Western blot shown in Fig. 2A, in precipitates ob-
tained from cells treated with FMP-API-1, the signals were
significantly reduced (Fig. 2C). As expected, in the presence of
excess cAMP, the cAMP-agarose did not recover detectable
amounts of RII-binding proteins.
Taken together, these experiments show that FMP-API-1
and FMP-API-1/27 inhibit the interaction of endogenous
AKAPs with PKA in vitro and in cultured cells in vivo. In ad-
dition, the data underline that the molecule is membrane-
permeable, as predicted from its compliance with the Lipinski
rules (29).
FMP-API-1 Activates PKA but Not Other Kinases—The
binding region of FMP-API-1 may involve the autoinhibitory
region and/or the nucleotide binding regions of regulatory
subunits (Fig. 1, F–H). Thus, FMP-API-1 might also modulate
PKA activity. To test this hypothesis, an in vitro PKA activity
assay was performed (Fig. 3A). RII subunits bind to the cata-
lytic subunits and potently inhibit their activity. cAMP causes
the dissociation of C subunits from RII subunits and thereby
activation of the catalytic subunits. RII subunits were
titrated to catalytic subunits to limit catalytic subunit activity
to40% (Fig. 3A, left). The addition of either cAMP (5 M) or
FMP-API-1 (100 M and 1 mM) induced an increase in the
activity of the catalytic subunits in the presence of RII sub-
units, suggesting that FMP-API-1 binding to regulatory sub-
units (Fig. 1) dissociates catalytic from regulatory subunits.
The effect of FMP-API-1 on the interaction of RII and C sub-
units was also tested in precipitation assays using HEK293
cells and neonatal cardiac myocytes. RII subunits were im-
munoprecipitated from untreated cells and cells preincubated
with FMP-API-1 (100 M), and co-immunoprecipitated C
subunits were detected by Western blotting (Fig. 3B). The
presence of FMP-API-1 reduced the amount of co-immuno-
precipitated C subunits in both cell types (Fig. 3A shows a
representative experiment using HEK293 cells). This is in line
with the activation of PKA observed in vitro. To further test
FIGURE 2. FMP-API-1 disrupts AKAP-PKA interactions in cardiac myo-
cytes. A, rat neonatal cardiac myocytes were treated with FMP-API-1
(300 M) or ISO (100 nM) either alone or in combination (FMP-API-1 
ISO). DMSO-treated (0.1%) cells served as control. Immunoprecipitation
(IP) was performed with anti-AKAP150 antibody or preimmune serum as
a negative control (top). WB, Western blot. Middle, agarose gel from a
representative experiment showing PepTag A1 peptide phosphorylation
by PKA co-immunoprecipitated with AKAP150. Bottom, the amounts of
phosphorylated and non-phosphorylated PepTag A1 peptides were
densitometrically evaluated, and the ratio was calculated. PKA activity in
the precipitates is expressed as the ratio of phosphorylated to non-
phosphorylated PepTag A1 peptides. Values are mean  S.E. (error bars);
***, significantly different from controls (p  0.001; n  7 independent
experiments for each condition). B, left, cAMP-agarose precipitates were
obtained from rat neonatal cardiac myocytes treated with FMP-API-1 (100
M) or the FMP-API-1 solvent DMSO (0.1%; control). As a control, excessive
cAMP (50 mM) was added to lysates obtained from control cells. This pre-
vents binding of regulatory PKA subunits to cAMP-agarose and thereby
precipitation of AKAPs. RII, Yotiao, AKAP150, and AKAP18were detected
by Western blotting. Right, semiquantitative evaluation of the Western blots
shown on the left. Signal intensities were densitometrically determined.
Shown is the relative amount of RII subunits precipitated in the absence or
presence of FMP-API-1 and the ratios of AKAPs/RII. *, p 0.05, statistically
significant difference versus RII. C, left, detection of AKAPs in cAMP-aga-
rose precipitates (obtained as described in B) by RII overlay assay. Proteins
were separated by SDS-PAGE, blotted onto filters, and overlaid with 32P-
labeled RII subunits of PKA. Binding is detected by autoradiography. Shown
are representative results from three independent experiments. Right, semi-
quantitative evaluation of the autoradiographs shown on the left. Signal
intensities of all bands in each lane were densitometrically determined. *,
p 0.05.
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whether FMP-API-1 increases PKA activity in cells, cardiac
myocytes were incubated with FMP-API-1, the cells were
lysed, lysates were cleared from cell debris, and PKA activity
was measured. Fig. 3C shows that 100 M FMP-API-1 acti-
vated PKA and that 300 M FMP-API-1 increased PKA activ-
ity to a level similar to that reached if the cells had been
treated with isoproterenol (100 nM). In combination, FMP-
API-1 and isoproterenol acted additively. Both the FMP-
API-1- and isoproterenol-induced activity increases were pre-
vented with the PKA inhibitor, H89.
Further in vitro kinase assays investigated whether high
concentrations of FMP-API-1 affected catalytic subunit activ-
ity in the absence of regulatory subunits. The activity of cata-
lytic subunits of PKA was not even affected by concentrations
of FMP-API-1 as high as 1 mM, whereas the specific inhibitor
peptide derived from the heat-stable protein kinase inhibitor
fully blocked catalytic subunit activity (Fig. 3A, right). FMP-
API-1 (100 M) did not activate in in vitro kinase assays
ErbB1, MEK1, ERK1 and -2, ROCK1 and -2, PKC, CaMKII,
and GSK3 (supplemental Fig. 3). Indeed, these kinases were
inhibited to a minor extent10–17%, whereas CaMKII and
GSK3 were somewhat more sensitive to the compound (they
were inhibited by 36 and 25%, respectively; supplemental Fig.
3). We have chosen these kinases because they are involved in
controlling cardiac myocyte functions, including contractility.
FMP-API-1 Inhibits -Adrenoreceptor-mediated Increases
of L-type Ca2- and IKs K Channel Currents—Functional
consequences of the disruption of AKAP-PKA interactions in
rat neonatal cardiac myocytes were examined by whole-cell
patch clamp experiments. -Adrenoreceptor stimulation
causes enhanced Ca2 entry into cardiac myocytes through
PKA phosphorylation of L-type Ca2 channels. The phosphor-
ylation is facilitated by AKAP18 tethering PKA to the chan-
nel (31). Fig. 4A depicts patch clamp experiments using rat
neonatal cardiac myocytes. These show that FMP-API-1 (100
M), applied through the patch pipette, abolished Ca2 cur-
rent increases stimulated by the -adrenergic agonist ISO
(100 nM). The inhibitory effect of FMP-API-1 was similar to
that achieved using the PKA anchoring disruptor peptide
AKAP18-L314E (12). FMP-API-1 (100 M) did not inhibit
L-type Ca2 currents stimulated by the channel activator Bay
K 8644, indicating that FMP-API-1 does not interfere with
the channels but rather disrupts the AKAP18-PKA
interaction.
The AKAP Yotiao tethers PKA to IKs K channels and
thereby facilitates channel phosphorylation by PKA (32). In
order to test whether the observed inhibition of the Yotiao-
PKA interaction by FMP-API-1 (Fig. 2B) prevents -adreno-
receptor-induced increases in IKs currents, whole-cell patch
clamp experiments were carried out (Fig. 4B). IKs K channel
currents are not detectable in neonatal cardiac myocytes.
Therefore, the pore-forming channel subunit KCNQ1 and its
FIGURE 3. FMP-API-1 activates PKA. A, left, recombinant RII (0.013 ng)
and catalytic subunits (0.0167 mg/ml) of PKA were incubated with
DMSO (0.1%), the solvent of FMP-API-1 as a control, and cAMP and/or
FMP-API-1 as indicated, and PKA activity was assessed using the PepTag
A1 peptide phosphorylation assay as described in the legend to Fig. 2
(mean  S.E. (error bars), three independent experiments). *, p  0.05
statistically significant difference versus DMSO. Right, recombinant cata-
lytic subunits alone were incubated with DMSO (0.1%), FMP-API-1, or the
specific PKA inhibitor peptide (protein kinase inhibitor; PKI) as indicated,
and PKA activity was assessed (mean  S.E., three independent experi-
ments). *, p  0.05; **, p  0.005 statistically significant difference versus
DMSO. B, top, HEK293 cells were incubated with FMP-API-1 (100 or 300
M) for 30 min. RII subunits were immunoprecipitated (IP), and co-im-
munoprecipitated catalytic C subunits of PKA were detected by West-
ern blotting (WB). Bottom, semiquantitative evaluation of the Western
blot shown in the top. The signal intensities were densitometrically de-
termined. Shown are means from two independent experiments. C, rat
neonatal cardiac myocytes were treated with DMSO (0.1%) as a control,
FMP-API-1, isoproterenol, H89, or the indicated combinations of agents. Cell
lysates were prepared and cleared by centrifugation, and PKA activity in the
supernatants was assessed (mean S.E., three independent experiments).
*, p 0.05; **, p 0.005; ***, p 0.001, statistically significant difference
versus DMSO. #, p 0.05 as indicated.
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regulatory subunit KCNE1 were transiently expressed as fu-
sion protein in COS-M7 cells to generate functional channels
(26). For activation of PKA, the cells were perfused through
the patch pipette with cAMP together with the protein phos-
phatase inhibitor, okadaic acid. This treatment did not affect
K currents (Fig. 4B, top and bottom). However, if the fusion
protein and Yotiao were co-expressed, cAMP together with
okadaic acid enhanced K currents (Fig. 4B,middle and bot-
tom). The appearance of the current was prevented by chal-
lenge of cells with FMP-API-1 (100 M). The results support
the notion that FMP-API-1 prevents Yotiao-dependent teth-
ering of PKA to the channel and thereby the Yotiao-depen-
dent PKA regulation of the channel.
FMP-API-1 Enhances -Adrenoreceptor-induced cAMP
Formation—Prostaglandins E1 and E2 (PGE1 and PGE2) in-
duce cAMP synthesis through stimulation of EP2 and EP4 re-
ceptors (33). In HEK293 cells, a multiprotein complex termi-
nates PGE1-induced cAMP synthesis by establishing a
negative feedback loop. The components include among oth-
ers the AKAP gravin, PKA and cAMP phosphodiesterase-4D3
(PDE4D3; Fig. 5A, top) (25). The PGE1-induced rise in cAMP
activates gravin-bound PKA that, in turn, phosphorylates
PDE4D3, thereby enhancing its activity and degradation of
cAMP in the vicinity of adenylyl cyclases. In addition,
AKAP79 targets PKA to adenylyl cyclases V and VI, as shown
in both HEK293 cells and mouse brain, thereby facilitating
PKA phosphorylation and inhibition of the cyclases (34).
Initially, we tested the impact of FMP-API-1 on the nega-
tive feedback regulation of cAMP levels in HEK293 (Fig. 5A).
The cells were transiently transfected to express CNGC as
reporters for near membrane cAMP synthesis and loaded
with the Ca2 indicator Fura-2/AM. Stimulation with PGE1
(1 M) induces synthesis of cAMP, which binds to CNGC,
opening the channels and facilitating Ca2 entry. The rise in
Ca2 is reflected by a transient rise in fluorescence signals
(Fig. 5A,middle, Control). If degradation of cAMP is pre-
vented with rolipram, a specific inhibitor of PDE4 enzymes
(35), or in the presence of the PKA inhibitor H89 or if PKA
was uncoupled from AKAPs by the PKA anchoring disruptor
peptide Ht31 (10) or with our novel small molecule AKAP-
PKA disruptor FMP-API-1 (1 M), the Ca2 signal (reporting
cAMP) persisted (Fig. 5A). An inactive control peptide,
Ht31-P (10), not binding PKA, did not influence cAMP syn-
thesis. Similar results were obtained if -adrenoceptors were
stimulated with isoproterenol (100 nM; Fig. 5A, bottom). FMP-
API-1 concentration-dependently changed the transient re-
sponse into a sustained elevation of cAMP. Thus, FMP-API-1
has a similar effect as the well characterized peptide Ht31.
Cardiac myocytes are a major site of expression of adenylyl
cyclases V and VI (36) and PDE4 (35, 37). Therefore, we used
FIGURE 4. FMP-API-1 inhibits -adrenoreceptor-induced L-type Ca2-
and IKs K
 channel currents. A, L-type Ca2 channel currents in rat
neonatal cardiac myocytes were measured using the patch clamp tech-
nique. The cells were left untreated (without) or perfused with FMP-
API-1 (100 M) via the patch pipette as indicated. Increases in Ca2 cur-
rents were induced by ISO (1 M) (top) or the channel activator Bay
K8644 (Bay; 70 nM) (bottom). ISO and Bay were washed out with buffer
where indicated (wash). Time courses of normalized current densities
are shown. Right, summaries, means  S.E.; *, significantly different from
untreated cells, p 	 0.01; n is indicated by the numbers in parentheses.
B, CHO cells transiently expressing either IKs channels alone (KCNE1-KCNQ1
fusion protein; top) or in combination with Yotiao (middle) were subjected
to a pulse protocol to elicit channel activity. Cells were preincubated with
compound and dialyzed with cAMP (200 M) and okadaic acid (OA; 0.2 M)
in the absence or presence of FMP-API-1 (100 M) via the patch pipette.
Time courses of normalized current densities are shown. Bottom, summary.
Values are mean S.E. (error bars). *, significantly different from isoprotere-
nol-treated cells, p	 0.01. n is indicated by the numbers in parentheses.
Small Molecule Inhibitors of AKAP-PKA Interactions
MARCH 18, 2011•VOLUME 286•NUMBER 11 JOURNAL OF BIOLOGICAL CHEMISTRY 9089
 at U
N
IV
ERSITY
 O
F SZEG
ED
 on July 17, 2019
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Small Molecule Inhibitors of AKAP-PKA Interactions
9090 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 286•NUMBER 11•MARCH 18, 2011
 at U
N
IV
ERSITY
 O
F SZEG
ED
 on July 17, 2019
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
FMP-API-1 to determine whether cAMP synthesis in cardiac
myocytes includes a component of negative feedback inhibi-
tion controlled by AKAP-PKA interactions. In rat neonatal
cardiac myocytes, FMP-API-1 (50 M) alone did not alter the
cAMP level, whereas it augmented isoproterenol-induced
cAMP synthesis by 1 order of magnitude, leading to a
decrease of the EC50 value of isoproterenol from 724 nM
(354–1479 nM, 95% confidence interval of the mean) to 95 nM
(57–158 nM, 95% confidence interval of the mean) (Fig. 5B).
FMP-API-1/27 had a similar effect (supplemental Fig. 2B). If a
constant concentration of isoproterenol (100 nM) was applied
and FMP-API-1 was titrated in the concentrations indicated
(Fig. 5B,middle), the EC50 for cAMP generation was 3.2 M
(95% confidence interval of the mean). Because FMP-API-1
and FMP-API-1/27 interfere with AKAP-PKA interactions
(Figs. 1 and 2), these observations are consistent with the hy-
pothesis that the compounds interfere with a negative feed-
back regulation of cAMP synthesis in cardiac myocytes that is
controlled by AKAP-PKA interactions to limit -adrenore-
ceptor-induced cAMP synthesis. The possibility cannot be
excluded that the compound interferes with PKA-dependent
phosphorylation of PDE4. Interference with the PKA-depen-
dent phosphorylation of PDE4 and thus an increase in its ac-
tivity (38) in response to -adrenoreceptor stimulation would
contribute to enhancing cAMP synthesis. Thus, the observed
rise in cAMP most likely results from both displacement of
PKA from the cyclase and inhibition of PDE4 phosphoryla-
tion. Therefore, the activation of PKA through FMP-API-1
(Fig. 3) is due to its direct effect on the kinase and to its en-
hancing effect on the cAMP level.
PGE-dependent signaling in cardiac myocytes leads to in-
creases in cAMP, activating predominantly compartmental-
ized PKA type I, and does not cause phosphorylations of
phospholamban (PLN) and c-TnI (39). Consistently, PGE sig-
naling has not been found to involve either AKAP-PKA- or
AKAP-adenylyl cyclase interactions (40, 41). In line with these
observations, FMP-API-1 did not enhance either PGE1- or
PGE2-induced increases of cAMP in neonatal cardiac myo-
cytes (Fig. 5B, bottom).
It is likely that FMP-API-1 has similar effects on cAMP
levels in other cells if they are controlled by AKAP-PKA inter-
actions. In contrast to cardiac myocytes, adenylyl cylcase acti-
vation is associated with relaxation in smooth muscle cells.
Increases in cAMP levels through -adrenoreceptor activa-
tion promote relaxation of the myometrium via activation of
PKA (42). The underlying molecular mechanism involves in-
hibition of phospholipase C, which is dependent on the
plasma membrane-associated interaction of PKA with
AKAP150 (43). We investigated the effect of FMP-API-1 on
the relaxation of pregnant rat uterus and on cAMP formation.
Potassium chloride (KCl) stimulates Ca2 influx in the myo-
metrium by membrane depolarization and evokes contrac-
tions. The 2-adrenoreceptor agonist terbutaline inhibited the
KCl-evoked contractions by 41%. In the presence of FMP-
AP-1 (1 M), the maximal contraction-inhibiting effect of ter-
butaline was increased to 75% (p 0.05; Fig. 5C). The ter-
butaline-induced cAMP accumulations were increased
concentration-dependently by 1 and 10 M FMP-API-1 (Fig.
5C). These results indicate that regulation of cAMP synthesis
in the myometrium, like that in cardiac myocytes, is con-
trolled by AKAP-PKA interactions terminating -adrenore-
ceptor-induced cAMP synthesis. Collectively, these data and
our analyses of the effects of FMP-API-1 on PKA-dependent
ion channel regulation establish that FMP-API-1 potently
interferes with compartmentalized PKA signaling involving
AKAP-PKA interactions.
FMP-API-1 Increases PKA-mediated Phosphorylations of
Phospholamban and Cardiac Troponin I but Does Not Cause
Global Phosphorylation of PKA Substrates or Affect PDEs and
Protein Phosphatases—The dual effect of FMP-API-1 on PKA
(i.e. displacement of PKA from AKAPs and activation of the
kinase) suggested that the molecule causes increases in the
phosphorylation of PKA substrates in the vicinity of AKAPs,
where PKA is concentrated, and generally of substrates in
particulate compartments, such as the plasmalemma, because
PKA is targeted to such compartments by AKAPs.
Major substrates of PKA in cardiac myocytes are PLN and
cardiac troponin I (c-TnI; see Introduction). PLN is anchored
to the sarcoplasmic reticulum (SR) and c-TnI is located at the
plasmalemma. In response to -adrenergic stimulation, PKA
phosphorylates PLN on serine 16 (44) and c-TnI at serines 23
and 24 (45). The PKA-mediated PLN phosphorylation de-
pends on the interaction of PLN with AKAP18 (22). Using
an antibody that specifically detects the PKA-phosphorylated
PLN, an increase in the phosphorylation was observed in re-
sponse to challenge with FMP-API-1 (100 and 300 M, 2.6-
and 9.3-fold, respectively), isoproterenol (100 nM, 14-fold), or
the combination of FMP-API-1 (100 M) and isoproterenol
FIGURE 5. In cardiac myocytes, negative feedback regulation of -adrenoreceptor-induced cAMP synthesis by PKA is based on AKAP-PKA interac-
tions. A, top, model of the negative feedback regulation of cAMP synthesis in HEK293 cells (25). Stimulation of EPs with PGE1 or of -adrenoceptors (-AR)
with adrenergic agonists, such as norepinephrin (NE) or isoproterenol, activates the G protein Gs, which in turn stimulates adenylyl cyclase (AC). The conse-
quent rise in cAMP activates AKAP-bound PKA. AKAP-associated PKA phosphorylates (P) gravin-associated cAMP phosphodiesterase PDE4D, thereby in-
creasing PDE activity and thus inhibiting cAMP accumulation. In HEK293 cells, the AKAP involved is gravin.Middle, HEK293 cells, expressing gravin and ad-
enylyl cyclase endogenously, were transiently transfected to express CNGC and loaded with the Ca2 indicator Fura-2. The cells were preincubated with the
PDE4 inhibitor rolipram, the PKA inhibitor H89, the PKA-anchoring disruptor peptide Ht31, the inactive control peptide Ht31P, or FMP-API-1 in the indicated
concentrations. The peptides were rendered membrane-permeable by coupling to stearate (St-Ht31 and St-Ht31P). At the indicated time point, the cells
were stimulated with PGE1 to induce cAMP synthesis. The rise in cAMP opens CNGC, and Ca
2 enters the cells, binds to Fura-2, and thereby generates fluo-
rescence signals, which were imaged. Bottom, the same experiment as described above was carried only with isoproterenol (100 nM) as an agonist. Shown
are representative results from three independent experiments. B, rat neonatal cardiac myocytes were treated with the indicated concentrations of isoprot-
erenol, PGE1, and PGE2 in the absence or presence of FMP-API-1 in the indicated concentrations, and cAMP levels were determined by radioimmunoassay.
n 3 independent experiments for each experiment. C, top, contractions of uterine rings isolated from rats on day 22 of pregnancy. The rings were treated
with the 2-adrenoreceptor agonist terbutaline in the indicated concentrations or a combination of terbutaline and FMP-API-1. The responses are ex-
pressed as the percentage inhibition of the rhythmic contractions evoked by KCl (mean S.E. (error bars); n 6 in each group). Bottom, cyclic AMP accu-
mulations in rat uterine tissue isolated as indicated above were determined by enzyme immunoassay. The tissue was incubated as indicated (means S.E.;
n 6 in all groups). Statistically significant differences are indicated as follows: *, p 0.05; ***, p 0.001; #, p 0.05; ###, p 0.001.
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(18-fold; Fig. 6A). c-TnI is an AKAP itself (46). The phospho-
rylation of c-TnI increased in response to FMP-API-1 (100
and 300 M, 2- and 3-fold, respectively) or to isoproterenol
(100 nM, 6-fold; Fig. 6B). In combination with isoproterenol,
FMP-API-1 did not elevate the phosphorylation level ob-
served in response to isoproterenol alone, presumably be-
FIGURE 6. FMP-API-1 enhances PKA-dependent phosphorylation of PLN and c-TnI in cardiac myocytes but does not globally induce phosphoryla-
tion of PKA substrates or affect phosphatase or PDE4 activities. Rat neonatal cardiac myocytes were incubated with the solvent of FMP-API-1, DMSO
(0.1%, control), FMP-API-1, isoproterenol, the PKA inhibitor H89, or the indicated combinations of agents. A, Western blot analysis with antibodies recogniz-
ing PKA-phosphorylated serine 16 of PLN or anti-calsequestrin (loading control). Results are representative of at least five independent experiments for
each condition. Bottom, semiquantitative analysis of the amounts of phosphorylated PLN. Western blot signals were analyzed densitometrically (means
S.E. (error bars); at least five independent experiments per condition). *, p 0.05; **, p 0.005, statistically significant difference from DMSO-treated control
cells. B, non-phosphorylated and phosphorylated c-TnI (c-TnI and p-TnI) were detected by Western blotting. Shown is one representative result from two
independent experiments. Bottom, semiquantitative analysis of the amounts of phosphorylated c-TnI (mean of two independent experiments). C, detection
of proteins phosphorylated by PKA at the consensus site RRXS/T. Shown is one representative result from two independent experiments. Arrows and plus
signs, proteins whose PKA phosphorylation increases in response to forskolin, isoproterenol, or FMP-API-1 (100 and 300 M). H89 reduced these phosphor-
ylation events; arrows andminus signs, proteins whose PKA phosphorylation increases upon challenge with forskolin and isoproterenol but not upon chal-
lenge with FMP-API-1. The forskolin- and isoproterenol-induced phosphorylations were inhibited by H89. D, calcineurin and total phosphatase activities
were determined. DMSO (0.1%) or FMP-API-1 were added as indicated (n 4, means S.E.). E, FMP-API-1 does not influence PDE4 activity in cardiac myo-
cytes. Rat neonatal cardiac myocytes were left untreated or incubated with FMP-API-1 in the indicated concentrations. Cell lysates were prepared, and PDE4
activities were measured using 20 g of protein, 25 l of cell lysates.
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cause isoproterenol alone induces saturating phosphorylation
of c-TnI. The effect of FMP-API-1 (300 M) was blocked by
the PKA inhibitor H89 (30 M).
To rule out the possibility that FMP-API-1 induces a global
increase in the phosphorylation of PKA substrates, cardiac
myocytes were incubated with the molecule, and phosphory-
lated PKA substrates were detected with an antibody directed
against the consensus motif, RRX(S/T), phosphorylated by
PKA (Fig. 6C). Proteins specifically phosphorylated by PKA
can be distinguished from proteins not phosphorylated by this
kinase because their phosphorylation increases in response to
isoproterenol or forskolin and is inhibited by H89. Fig. 6C
shows two proteins with molecular masses of 250 and 27 kDa
(indicated by arrows and plus signs), whose PKA phosphoryla-
tion increases in response to forskolin, isoproterenol, or FMP-
API-1 (100 and 300 M). H89 reduced these phosphorylation
events. The phosphorylation of two other proteins, indicated
by arrows andminus signs, increased upon challenge with
forskolin and isoproterenol but not upon challenge with
FMP-API-1. The forskolin- and isoproterenol-induced phos-
phorylations were again inhibited by H89. Thus, FMP-API-1
does not globally increase phosphorylation of PKA substrates.
Moreover, FMP-API-1 did not inhibit PDE or protein phos-
phatase activities in lysates from rat neonatal cardiac myo-
cytes, indicating that the increased phosphorylation of pro-
teins by PKA is not due to inhibition of these enzymes (Fig. 6,
D and E). Thus, FMP-API-1-activated PKA most likely phos-
phorylates a specific subset of target proteins rather than
globally the entire pool of possible species. The phosphoryla-
tion of a subset of targets is probably catalyzed by specific
compartmentalized pools of PKA. Toxic effects of the com-
pounds in the concentrations used were not observed (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide color-
imetric assay; data not shown).
FMP-API-1 Increases Contractility of Cultured Cardiac
Myocytes and Isolated Rat Hearts—The observed activation of
PKA and increases in PLN and c-TnI phosphorylations by
FMP-API-1 led us to investigate whether FMP-API-1 affects
the contractility of cardiac myocytes. PKA phosphorylation of
PLN increases contraction and of c-TnI enhances relaxation
(47, 48). Compared with the solvent DMSO (0.1%) isoprotere-
nol (100 nM) or FMP-API-1 alone (10 M) increased rates of
shortening, of relengthening, and also of absolute cell short-
ening by 15–20% (Fig. 7A). FMP-API-1 consistently inhibited
the isoproterenol-induced increases, although the differences
did not reach statistical significance. In isolated Langendorff
hearts, DMSO also did not have an effect, but FMP-API-1 (10
M) caused a small but significant increase of 16% in the rate
of left ventricular pressure development of 13% in the con-
traction rate and of 18% in the maximal relaxation rate of the
heart (Fig. 7B). As expected, isoproterenol increased the three
parameters severalfold. The isoproterenol-induced increases
of all three parameters were inhibited by around 50% in the
presence of FMP-API-1 (10 M). Thus, the increased level of
PKA phosphorylation of PLN in the presence of FMP-API-1 is
in line with the observed increase of contraction. The increase
in PKA phosphorylation of c-TnI in response to FMP-API-1
is consistent with the observed FMP-API-1-induced enhance-
ment of relaxation. The inhibitory effect of FMP-API-1 on the
isoproterenol-induced increases in left ventricular pressure
development, contraction rate, and the maximal relaxation
rate of the hearts is consistent with the observed inhibitory
effect of the small molecule on the isoproterenol-induced in-
creases in L-type Ca2 channel currents (Fig. 4). Taken to-
gether, the data indicate that FMP-API-1 leads to both posi-
tive inotropic and lusitropic effects by interference with
compartmentalized cAMP/PKA signaling.
DISCUSSION
Based on high throughput screening and subsequent chem-
ical modification, we have identified small molecules, namely
FMP-API-1 and its derivative FMP-API-1/27, that disrupt
interactions between AKAPs and PKA. The D/D domain at
the N terminus of the RII subunits is the interface at which
AKAPs interact through their RII-binding domains. Together,
NMR, Biacore, and in vitro kinase assays show that the mole-
cules reversibly bind to RII subunits C-terminal of the D/D
domain (Fig. 1, F–H, and supplemental Fig. 1). To date, the
FIGURE 7. FMP-API-1 increases contractility of cultured adult rat cardiac
myocytes and isolated rat hearts. A, adult rat ventricular myocytes were
isolated, loaded with Fura-2/AM, and placed under field stimulation. Rates
of cell shortening and relengthening and absolute cell shortening were
measured under basal conditions (control) and in the presence of the FMP-
API-1 solvent DMSO (0.1%), ISO (100 nM), or FMP-API-1 (10 M; mean S.E.
(error bars), n 7 measurements for each condition from at least three dif-
ferent cultures). B, left ventricular pressure development, contraction, and
relaxation rates were measured in isolated Langendorff rat hearts perfused
with vehicle (0.1% DMSO, control), isoproterenol (100 nM), FMP-API-1 (10
M), or isoproterenol together with FMP-API-1. n 6 hearts were used for
each treatment (mean S.E.). *, p 0.05 versus basal. **, p 0.005; ***, p
0.001 versus basal.
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D/D domain has been the only portion of the RII subunits
implicated in either direct binding or regulation of binding to
AKAPs (5, 9). The fact that the new small molecule disruptors
so markedly affect the binding of AKAPs to regulatory sub-
units without interaction with the core AKAP-regulatory sub-
unit interface and the fact that they act additively with Ht31
peptides (Fig. 1E) point to the binding site as a so far un-
known allosteric regulatory site. The small molecules inter-
fere with cAMP binding of the regulatory subunits (Figs. 1H
and 2B). It is currently not known whether this occurs
through blockade of the cyclic nucleotide-binding domain or
binding of the molecule outside the cyclic nucleotide-binding
domain, which might lead to a conformational change inhibit-
ing the interaction with cAMP. The region following N-ter-
minally the D/D domain contains an autoinhibitory site
(amino acids 92–102 in human RII) (49). This inhibitory site
binds to the active site cleft of the catalytic subunit in the ho-
loenzyme. The interaction of a small molecule within this re-
gion could prevent the inhibitory functioning of this part of
the protein, thereby leading to the dissociation, and hence
activation, of catalytic subunits. Taken together, not only does
the D/D domain seem to interact with RII-binding domains of
AKAPs, but additional regions of the regulatory PKA subunits
are involved in the interaction.
Interference of the small molecules with the autoinhibitory
site may underpin the observed increase in catalytic activity
(Fig. 3). In order to fully understand the molecular mecha-
nisms underlying the effects of FMP-API-1 on AKAP-PKA
interactions and PKA activity, solved structures of complexes
of full-length RII subunits with and without compounds (and
of AKAP-R subunit complexes) are needed. However, so far,
any attempt to obtain three-dimensional structures of full-
length RII subunits has not been successful. In addition, such
studies may require compounds binding with higher affinity
to RII subunits than those currently available. Our attempts to
exactly map the binding region of FMP-API-1 using further
truncated versions of RII were compromised because the
required recombinant proteins were insoluble (e.g. RII 87–
156) or apparently did not fold correctly (e.g. RII 1–156, in-
dicated by STD NMR experiments; data not shown). We did
not consider knockdown of RII subunits as a further approach
to confirm that PKA is the FMP-API-1 target because knock-
down would lead to a reduction of experimentally detectable
RII-AKAP interactions.
With respect to inhibition of AKAP-PKA interactions,
FMP-API-1 and derivatives resemble PKA anchoring disrup-
tor peptides, such as Ht31 and AKAP18-derived peptides,
which block AKAP-PKA interactions by binding to the D/D
domain of regulatory subunits (6, 10, 12, 50). Several experi-
ments show that FMP-API-1 and the peptides have similar
effects on cellular functions. For example, both agents ablate
-adrenoreceptor-induced increases in L-type Ca2 and IKS
channel currents and inhibit negative feedback regulation of
adenylyl cyclase-dependent cAMP synthesis (Figs. 4 and 5)
(12, 25, 32, 51). Thus, blocking of the canonical AKAP-inter-
acting site, namely the D/D domain, either directly with pep-
tides or indirectly through the binding of a small molecule to
an allosteric site, inhibits AKAP-RII subunit interactions. Al-
though the efficacy for inhibition of AKAP-RII interactions
with the small molecules identified is considerably lower than
that with the peptides (IC50 values are M versus nM), a major
advantage of small molecules compared with peptides is their
wider applicability for cell and animal experiments. Efficient
transfer of peptides to disrupt the interactions in cells and
living animals requires costly efforts, including viral transfec-
tion or generation of cell-penetrating peptides (12, 50, 52, 53).
Thus, the small molecules discovered here pave the way to
new approaches for elucidating functions of AKAP-PKA in-
teractions in vivo.
In cardiac myocytes, FMP-API-1 enhances -adrenorecep-
tor-induced increases in cAMP levels (Fig. 5) and thus reveals
a novel mechanism terminating -adrenoreceptor-dependent
signaling in the heart. AKAP79/150 tethers PKA to adenylyl
cyclases V and VI to phosphorylate it, rapidly terminating
cAMP synthesis upon activation of PKA in the brain and in
HEK293 cells (34, 54). Because adenylyl cyclases V and VI are
highly relevant cyclases in cardiac myocytes (55), and FMP-
API-1 disrupts the AKAP150-PKA interaction in these cells
(Fig. 2), it is conceivable that the compound blunts negative
feedback regulation of these cyclases by interference with this
interaction. However, other AKAPs may link PKA to adenylyl
cyclases in cardiac myocytes. For example, mAKAP is asso-
ciated with adenylyl cyclase V (54), and targeting of PKA by
Yotiao to various other adenylyl cyclases has recently been
observed in neurons (56). Further evidence confirming that
FMP-API-1 interferes with AKAP-PKA interactions that con-
trol adenylyl cyclase activities stems from the experiments in
uterine tissue (Fig. 5C). The molecule enhances -adrenore-
ceptor-induced cAMP production in uterus preparations,
presumably by interference with AKAP150-PKA interactions,
which play a role in controlling uterine contraction (57).
Thus, attenuation of adenylyl cyclase activity in response to
-adrenergic agonists regularly seems to rely on AKAP-PKA
interactions. Our analyses of the effects of FMP-API-1 on
prostaglandin E-stimulated adenylyl cyclase activity in cardiac
myocytes shows no FMP-API-1-dependent increase in cAMP
formation in response to either PGE1 or PGE2. The cognate
eicosanoid E prostaglandin receptors (EPs) couple to the Gs/
adenylyl cyclase system (33), and EP signaling mainly involves
compartmentalized PKA type I (39). AKAP-PKA interactions
have not been found to be involved in EP signaling (40, 41).
This is consistent with our observations that FMP-API-1 has
no effect on EP signaling. The negative feedback regulation
may involve PKA phosphorylation of PDE4. Inhibition of
AKAP-PKA interactions may reduce such phosphorylation
and thereby prevent enhanced cAMP degradation, which in
turn would contribute to elevation of the cAMP level in the
presence of the inhibitor.
The classical function of AKAPs is to concentrate PKA at
defined cellular sites. FMP-API-1 displaces PKA from
AKAP18 (Fig. 2), which tethers PKA to PLN (22), but this
does not result in lower levels of PLN phosphorylation. In
contrast, PKA-dependent phosphorylation of PLN in cardiac
myocytes is increased by FMP-API-1 challenge (Fig. 6). This
unexpected observation might be explained by the dual effect
of FMP-API-1. The FMP-API-1-induced direct activation of
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PKA leads to a local rise in the activity of PKA in the vicinity
of PLN where PKA is concentrated by AKAP18 (22). Acti-
vated PKA, in turn, phosphorylates this substrate. This seems
feasible when disruption (i.e. displacement of PKA from
AKAP18) and activation occur simultaneously. In addition,
the FMP-API-1-induced direct activation of PKA at the
AKAP18-PKA complex is probably enhanced through the
FMP-API-1-induced increases in cAMP levels in the presence
of adrenergic stimuli. The same reasons are likely to account
for the FMP-API-1-induced and PKA-dependent increases in
the phosphorylation of c-TnI, which is an AKAP itself (46).
The increased PLN and c-TnI phosphorylation would account
for the resulting positive inotropic and lusitropic effects on
cultured adult cardiac myocytes and isolated hearts (Fig. 7).
Bond and co-workers (13) and Patel et al. (50) had shown that
uncoupling of PKA from AKAPs with the PKA anchoring dis-
ruptor peptides Ht31 and AKAD in both cultured cardiac
myocytes and intact hearts decreases phosphorylation of PLN
and c-TnI (52, 53). The decrease is most likely due to the lack
of PKA-activating capabilities of the peptides (23). Bond and
co-workers (13, 53) observed a positive inotropic effect in re-
sponse to uncoupling PKA from AKAPs. Thus, either disrup-
tion of AKAP-PKA interactions alone or disruption of the
interactions in conjunction with PKA activation results in a
positive inotropic response. This outcome is potentially
highly relevant therapeutically because the development of
small molecule disruptors of AKAP-PKA interactions, either
with or without the ability to activate PKA, could pave the
way for a novel treatment of chronic heart failure. The classi-
cal approaches to elicit positive inotropic responses rely on
stimulation of -adrenoceptors, inhibition of cAMP synthesis
by blockade of PDE3, or inhibition of Ca2 channels with
heart glycosides. All of these approaches constitute initially
effective treatments, but chronic treatments based on these
concepts harm the failing heart and may even increase mor-
tality, as in the case of PDE3 inhibitors (by 28%) (58). One
reason for the failure of the approaches that elevate cellular
cAMP levels (-agonists and PDE blockers) may be that PKA
is constitutively and globally activated throughout the cells
(59). Local interference with defined cellular signaling pro-
cesses using AKAP-PKA disruptors may lead to a more effec-
tive treatment with fewer side effects because PKA may not
randomly phosphorylate its substrates (Fig. 6). Generally, the
specificity and diversity of protein-protein interactions per-
mits potentially highly selective pharmacological interference
with defined cellular processes and thus disruption of specific
protein-protein interactions promises better drugs (6).
Several observations underline that the effects of FMP-
API-1 and FMP-API-1/27 on cardiac myocytes and intact
hearts are not due to off target effects, although the chemical
structure of FMP-API-1 may suggest that it has the potential
to react with other proteins. (i) The identification of inactive
FMP-API-1 derivatives, such as FMP-API-1/26 (Fig. 1B), indi-
cates that the molecule does not nonspecifically bind to pro-
teins. (ii) FMP-API-1 interferes with -adrenergic but not
with PGE1/2 signaling (see above). (iii) FMP-API-1 did not
prevent direct activation of L-type Ca2 channels (Fig. 4A).
(iv) FMP-API-1 did not cause random increases of PKA-de-
pendent substrate phosphorylations (Fig. 6). (v) Activities of
several kinases (apart from PKA) that are involved in cardiac
myocyte control (including ErbB1, MEK1, ERK1 and -2,
ROCK1 and -2, PKC, CaMKII, and GSK3) are affected by
FMP-API-1 only to a minor extent (supplemental Fig. 3).
Consistently, antibodies directed against substrate proteins
phosphorylated by PKC, CaMKII, or Akt did not detect
changes in the phosphorylation pattern of proteins in cardiac
myocytes treated with FMP-API-1 for 30 min (100 or 300 M;
data not shown). (vi) FMP-API-1 did not influence protein
phosphatase and phosphodiesterase activities (Figs. 6, D and
E). Thus, the molecule apparently interferes selectively with
compartmentalized cAMP signaling.
In summary, the identification of the small molecules de-
scribed here lays the groundwork for the development of high
affinity small molecules disrupting the interaction of PKA
with AKAPs as well as for revealing novel mechanisms under-
lying this interaction. Such molecules provide an invaluable
tool for new approaches to study functions of AKAP-PKA
interactions in living cells and animals. Moreover, they have
the potential to be developed as highly targeted therapeutics
for the treatment of diseases that are associated with altered
cAMP signaling but that are not addressed sufficiently by
conventional pharmacotherapy, such as chronic heart failure.
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